中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 4
Apr.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(4): 909-914

Influence of white fat browning on nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2023.04.025
  • 1.

    The First Clinical Medical College of Henan University of Chinese Medicine, Zhengzhou 450046, China

  • 2.

    Department of Hepatology and Spleen-Stomach, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, China

Research funding:

National Natural Science Foundation of China (81473651);

Subject Construction Project of Traditional Chinese Medicine in Henan Province (STG-ZYXKY-2020024)

More Information
  • Corresponding author: ZHAO Wenxia, zhao-wenxia@163.com (ORCID: 0000-0001-6666-9469)
  • Received Date: 2022-08-02
  • Accepted Date: 2022-09-29
  • Published Date: 2023-04-20
    Abstract
  • Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease in which a large amount of fat accumulates in hepatocytes due to lipid metabolism disorders. Conventional anti-inflammatory and transaminase-lowering treatment regimens often have an unsatisfactory therapeutic effect, and restoring the normal biosynthesis and metabolism of lipids is the key to the treatment of NAFLD. Studies have shown that brown adipose tissue can improve metabolic diseases by enhancing insulin sensitivity and regulating lipid metabolism, and the treatment of NAFLD by promoting white fat browning has attracted wide attention in the medical field. This article reviews the mechanism of white fat browning in improving NAFLD and summarizes the hepatokines that can promote white fat browning, so as to provide new ideas for the clinical treatment of NAFLD.

     

    • FullText(HTML)
  • loading
    • References(46)
  • [1]
    National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.

    中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
    [2]
    BRAILLON A. Nonalcoholic steatohepatitis and hepatocellular carcinoma: Crying wolf or promoting healthy living?[J]. Clin Gastroenterol Hepatol, 2019, 17(11): 2383. DOI: 10.1016/j.cgh.2019.04.029.
    [3]
    ZHOU J, ZHOU F, WANG W, et al. Epidemiological features of NAFLD from 1999 to 2018 in China[J]. Hepatology, 2020, 71(5): 1851-1864. DOI: 10.1002/hep.31150.
    [4]
    ESLAM M, SANYAL AJ, GEORGE J, et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014.e1. DOI: 10.1053/j.gastro.2019.11.312.
    [5]
    ZENG J, FAN JG. Clinical significance of renaming nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2020, 36(6): 1205-1207. DOI: 10.3969/j.issn.1001-5256.2020.06.002.

    曾静, 范建高. 非酒精性脂肪性肝病更名的临床意义[J]. 临床肝胆病杂志, 2020, 36(6): 1205-1207. DOI: 10.3969/j.issn.1001-5256.2020.06.002.
    [6]
    MICHURINA SS, STAFEEV IS, MENSHIKOV MY, et al. Mitochondrial dynamics keep balance of nutrient combustion in thermogenic adipocytes[J]. Mitochondrion, 2021, 59: 157-168. DOI: 10.1016/j.mito.2021.05.001.
    [7]
    QIAN S, TANG Y, TANG QQ. Adipose tissue plasticity and the pleiotropic roles of BMP signaling[J]. J Biol Chem, 2021, 296: 100678. DOI: 10.1016/j.jbc.2021.100678.
    [8]
    WANG Z, WANG QA, LIU Y, et al. Energy metabolism in brown adipose tissue[J]. FEBS J, 2021, 288(12): 3647-3662. DOI: 10.1111/febs.16015.
    [9]
    PILKINGTON AC, PAZ HA, WANKHADE UD. Beige adipose tissue identification and marker specificity-overview[J]. Front Endocrinol (Lausanne), 2021, 12: 599134. DOI: 10.3389/fendo.2021.599134.
    [10]
    TABUCHI C, SUL HS. Corrigendum: Signaling pathways regulating thermogenesis[J]. Front Endocrinol (Lausanne), 2021, 12: 698619. DOI: 10.3389/fendo.2021.698619.
    [11]
    KAISANLAHTI A, GLUMOFF T. Browning of white fat: agents and implications for beige adipose tissue to type 2 diabetes[J]. J Physiol Biochem, 2019, 75(1): 1-10. DOI: 10.1007/s13105-018-0658-5.
    [12]
    LIU Q, NIU CY. From "two hit theory" to "multiple hit theory": Implications of evolution of pathogenesis concepts for treatment of non-alcoholic fatty liver disease[J]. World Chin J Dig, 2019, 27(19): 1171-1178. DOI: 10.11569/wcjd.v27.i19.1171.

    刘勤, 牛春燕. 由"二次打击"到"多重打击": 发病机制的演变带给非酒精性脂肪性肝病的治疗启示[J]. 世界华人消化杂志, 2019, 27(19): 1171-1178. DOI: 10.11569/wcjd.v27.i19.1171.
    [13]
    CANNON B, NEDERGAARD J. Brown adipose tissue: function and physiological significance[J]. Physiol Rev, 2004, 84(1): 277-359. DOI: 10.1152/physrev.00015.2003.
    [14]
    ORAVA J, NUUTILA P, LIDELL ME, et al. Different metabolic responses of human brown adipose tissue to activation by cold and insulin[J]. Cell Metab, 2011, 14(2): 272-279. DOI: 10.1016/j.cmet.2011.06.012.
    [15]
    ZHANG Q, YE H, MIAO Q, et al. Differences in the metabolic status of healthy adults with and without active brown adipose tissue[J]. Wien Klin Wochenschr, 2013, 125(21-22): 687-695. DOI: 10.1007/s00508-013-0431-2.
    [16]
    SHANKAR K, KUMAR D, GUPTA S, et al. Role of brown adipose tissue in modulating adipose tissue inflammation and insulin resistance in high-fat diet fed mice[J]. Eur J Pharmacol, 2019, 854: 354-364. DOI: 10.1016/j.ejphar.2019.02.044.
    [17]
    MA J, WANG Y, DING J, et al. SAHA induces white fat browning and rectifies metabolic dysfunctions via activation of ZFPs[J]. J Endocrinol, 2021, 249(3): 177-193. DOI: 10.1530/JOE-20-0472.
    [18]
    PENG WQ, XIAO G, LI BY, et al. l-Theanine activates the browning of white adipose tissue through the AMPK/α-Ketoglutarate/Prdm16 axis and ameliorates diet-induced obesity in mice[J]. Diabetes, 2021, 70(7): 1458-1472. DOI: 10.2337/db20-1210.
    [19]
    CHEN CC, KUO CH, LEU YL, et al. Corylin reduces obesity and insulin resistance and promotes adipose tissue browning through SIRT-1 and β3-AR activation[J]. Pharmacol Res, 2021, 164: 105291. DOI: 10.1016/j.phrs.2020.105291.
    [20]
    HSU JW, YEH SC, TSAI FY, et al. Fibroblast growth factor 21 secretion enhances glucose uptake in mono(2-ethylhexyl)phthalate-treated adipocytes[J]. Toxicol In Vitro, 2019, 59: 246-254. DOI: 10.1016/j.tiv.2019.04.021.
    [21]
    WANG Z, NING T, SONG A, et al. Chronic cold exposure enhances glucose oxidation in brown adipose tissue[J]. EMBO Rep, 2020, 21(11): e50085. DOI: 10.15252/embr.202050085.
    [22]
    SEEBACHER F, ZEIGERER A, KORY N, et al. Hepatic lipid droplet homeostasis and fatty liver disease[J]. Semin Cell Dev Biol, 2020, 108: 72-81. DOI: 10.1016/j.semcdb.2020.04.011.
    [23]
    GOOSSENS GH. The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function[J]. Obes Facts, 2017, 10(3): 207-215. DOI: 10.1159/000471488.
    [24]
    REYES-FARIAS M, FOS-DOMENECH J, SERRA D, et al. White adipose tissue dysfunction in obesity and aging[J]. Biochem Pharmacol, 2021, 192: 114723. DOI: 10.1016/j.bcp.2021.114723.
    [25]
    CORRÊA LH, HEYN GS, MAGALHAES KG. The impact of the adipose organ plasticity on inflammation and cancer progression[J]. Cells, 2019, 8(7): 662. DOI: 10.3390/cells8070662.
    [26]
    PIERANTONELLI I, SVEGLIATI-BARONI G. Nonalcoholic fatty liver disease: Basic pathogenetic mechanisms in the progression from NAFLD to NASH[J]. Transplantation, 2019, 103(1): e1-e13. DOI: 10.1097/TP.0000000000002480.
    [27]
    MORIGNY P, BOUCHER J, ARNER P, et al. Lipid and glucose metabolism in white adipocytes: pathways, dysfunction and therapeutics[J]. Nat Rev Endocrinol, 2021, 17(5): 276-295. DOI: 10.1038/s41574-021-00471-8.
    [28]
    di CIAULA A, PASSARELLA S, SHANMUGAM H, et al. Nonalcoholic fatty liver disease (NAFLD). Mitochondria as players and targets of therapies?[J]. Int J Mol Sci, 2021, 22(10): 5375. DOI: 10.3390/ijms22105375.
    [29]
    STANFORD KI, MIDDELBEEK RJ, TOWNSEND KL, et al. Brown adipose tissue regulates glucose homeostasis and insulin sensitivity[J]. J Clin Invest, 2013, 123(1): 215-223. DOI: 10.1172/JCI62308.
    [30]
    LIU X, WANG S, YOU Y, et al. Brown adipose tissue transplantation reverses obesity in Ob/Ob mice[J]. Endocrinology, 2015, 156(7): 2461-2469. DOI: 10.1210/en.2014-1598.
    [31]
    CHENG L, ZHANG S, SHANG F, et al. Emodin improves glucose and lipid metabolism disorders in obese mice via activating brown adipose tissue and inducing browning of white adipose tissue[J]. Front Endocrinol (Lausanne), 2021, 12: 618037. DOI: 10.3389/fendo.2021.618037.
    [32]
    CHEN Y, ZHAO YF, PENG XG, et al. Effect of irisin on fat and glucose and lipid metabolism in diet-induced obese mice[J]. Natl Med J China, 2021, 101(16): 1165-1170. DOI: 10.3760/cma.j.cn112137-20200902-02534.

    陈月, 赵宇飞, 彭新桂, 等. 鸢尾素对小鼠脂肪的作用及对饮食诱导肥胖小鼠糖脂代谢的影响[J]. 中华医学杂志, 2021, 101(16): 1165-1170. DOI: 10.3760/cma.j.cn112137-20200902-02534.
    [33]
    YAN J, NIE Y, CAO J, et al. The roles and pharmacological effects of FGF21 in preventing aging-associated metabolic diseases[J]. Front Cardiovasc Med, 2021, 8: 655575. DOI: 10.3389/fcvm.2021.655575.
    [34]
    MOURE R, CAIRÓ M, MORÓN-ROS S, et al. Levels of β-klotho determine the thermogenic responsiveness of adipose tissues: involvement of the autocrine action of FGF21[J]. Am J Physiol Endocrinol Metab, 2021, 320(4): E822-E834. DOI: 10.1152/ajpendo.00270.2020.
    [35]
    FISHER FM, KLEINER S, DOURIS N, et al. FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis[J]. Genes Dev, 2012, 26(3): 271-281. DOI: 10.1101/gad.177857.111.
    [36]
    GAICH G, CHIEN JY, FU H, et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes[J]. Cell Metab, 2013, 18(3): 333-340. DOI: 10.1016/j.cmet.2013.08.005.
    [37]
    WANG Y, MA C, SUN T, et al. Potential roles of bone morphogenetic protein-9 in glucose and lipid homeostasis[J]. J Physiol Biochem, 2020, 76(4): 503-512. DOI: 10.1007/s13105-020-00763-z.
    [38]
    CAPERUTO LC, ANHÊ GF, CAMBIAGHI TD, et al. Modulation of bone morphogenetic protein-9 expression and processing by insulin, glucose, and glucocorticoids: possible candidate for hepatic insulin-sensitizing substance[J]. Endocrinology, 2008, 149(12): 6326-6335. DOI: 10.1210/en.2008-0655.
    [39]
    HERRERA B, DOOLEY S, BREITKOPF-HEINLEIN K. Potential roles of bone morphogenetic protein (BMP)-9 in human liver diseases[J]. Int J Mol Sci, 2014, 15(4): 5199-5220. DOI: 10.3390/ijms15045199.
    [40]
    KUO MM, KIM S, TSENG CY, et al. BMP-9 as a potent brown adipogenic inducer with anti-obesity capacity[J]. Biomaterials, 2014, 35(10): 3172-3179. DOI: 10.1016/j.biomaterials.2013.12.063.
    [41]
    UM JH, PARK SY, HUR JH, et al. Bone morphogenic protein 9 is a novel thermogenic hepatokine secreted in response to cold exposure[J]. Metabolism, 2022, 129: 155139. DOI: 10.1016/j.metabol.2022.155139.
    [42]
    YANG S, LI S, LI XJ. MANF: A new player in the control of energy homeostasis, and beyond[J]. Front Physiol, 2018, 9: 1725. DOI: 10.3389/fphys.2018.01725.
    [43]
    WEI J, WANG C, YANG G, et al. Decreased circulating MANF in women with PCOS is elevated by metformin therapy and is inversely correlated with insulin resistance and hyperandrogenism[J]. Horm Metab Res, 2020, 52(2): 109-116. DOI: 10.1055/a-1082-1080.
    [44]
    WU T, LIU Q, LI Y, et al. Feeding-induced hepatokine, Manf, ameliorates diet-induced obesity by promoting adipose browning via p38 MAPK pathway[J]. J Exp Med, 2021, 218(6): e20201203. DOI: 10.1084/jem.20201203.
    [45]
    HASHIMOTO O, TSUCHIDA K, USHIRO Y, et al. cDNA cloning and expression of human activin betaE subunit[J]. Mol Cell Endocrinol, 2002, 194(1-2): 117-122. DOI: 10.1016/s0303-7207(02)00157-0.
    [46]
    HASHIMOTO O, FUNABA M, SEKIYAMA K, et al. Activin E controls energy homeostasis in both brown and white adipose tissues as a hepatokine[J]. Cell Rep, 2018, 25(5): 1193-1203. DOI: 10.1016/j.celrep.2018.10.008.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (337) PDF downloads(39) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return